Gottingen, Germany
Gottingen, Germany

Time filter

Source Type

This invention provides methods, compositions, and kits relating to detecting donor cell-free DNA in the circulation of an organ transplant recipient for the early identification of transplant rejection


Patent
Chronix Biomedical GmbH | Date: 2012-12-07

The invention provides methods and reagents for diagnosing prostate cancer that are based on the detection of biomarkers in the circulating nucleic acids from a patient to be evaluated.


Patent
Chronix Biomedical GmbH | Date: 2011-06-01

The invention provides methods and reagents for diagnosing prostate cancer that are based on the detection of biomarkers in the circulating nucleic acids from a patient to be evaluated.


Patent
Chronix Biomedical GmbH | Date: 2013-12-13

The invention provides methods and reagents for identifying personalized tumor biomarkers for a patient that has a solid tumor and methods of using such biomarkers to monitor patient responses to therapeutic treatments.


Patent
Chronix Biomedical GmbH | Date: 2015-07-15

The invention provides methods and reagents for diagnosing prostate cancer that are based on the detection of biomarkers in the circulating nucleic acids from a patient to be evaluated.


Patent
Chronix Biomedical GmbH | Date: 2011-04-18

The invention provides methods and reagents for diagnosing breast cancer that are based on the detection of biomarkers in the circulating nucleic acids from a patient to be evaluated.


LONDON--(BUSINESS WIRE)--A huge breakthrough in increasing the accuracy of cancer screening tests has been made. The method currently used has extremely poor accuracy. The new test developed by British, German and American scientists has a 91% accuracy, is expected to become the new norm and save many more lives as a result. The new test measures DNA in the blood as opposed to the current measurement of a specific blood protein. The first test in the world was successfully performed on a patient at a hospital in London. The new test is now being made available to health services worldwide. It has taken 15 years of research to develop, pioneered by Chronix Biomedical. Dr Nick Plowman, a Senior Clinical Oncologist at St. Bartholomew’s Hospital, Senior Lecturer at Queen Mary University of London and considered to be one of the UK’s leading experts in oncology is presenting the case at the William Harvey annual research day at St. Bartholomew’s Hospital. “The patient in today’s case report declined having a biopsy which limited our ability to fully comprehend his medical condition. Adding a genetic blood test (cell free cancer DNA circulating in the blood) clinched the diagnosis allowing us to make a treatment decision that resulted in a positive response. These liquid biopsies will become important in the fight against cancer. ” “Doctors need every tool at their disposal to make medically important decisions. Today’s report illustrates the clinical utility of adding the Chronix Biomedical blood test to the current test menu to assist oncologists in important treatment decisions. “


News Article | October 31, 2012
Site: www.xconomy.com

Chronix Biomedical is pioneering a breakthrough approach to the diagnosis and management of chronic diseases and cancer. It has developed proprietary technology that measures and categorizes circulating nucleic acids, DNA sequences circulating in the blood that are associated with specific changes in disease and health status.


LONDON--(BUSINESS WIRE)--Chronix Biomedical, the developer of blood tests that can be used for important applications in cancer and organ transplantation, announces that P. Nicholas Plowman MD, FRCR, FRCP has accepted the position of Chief Oncology Expert for Chronix Biomedical and will join the Company’s Medical Advisory Board. Dr Plowman has a distinguished career and is widely considered to be one of the UK’s leading oncology authorities. Since 2000 he has been the Head of Clinical Oncology at Bartholomew’s Hospital and the Royal London Hospital. He sits on the Hospital Councils of the Bartholomew’s Hospital and is also Senior Oncologist to the Hospital for Sick Children, Great Ormond Street. Dr Plowman has written over 300 research publications. His recognition as a leader and innovator in cancer diagnosis and treatment include the Roll of Honour by the International Union Against Cancer (UICC) in 1997 and the Royal College of Radiologists’ Frank Ellis Medal in 1999. Dr Plowman graduated from Cambridge with a Double First in Medical Sciences and a First in Natural Sciences. At Chronix, Dr Plowman will be advising on three plasma tests that the Company has developed: “We are delighted that Dr Plowman has agreed to take on such an important role for us. He has an extremely distinguished career and is regarded with great esteem by fellow professionals in his field. Our Second OpinionTM tests and cancer profiling tests will enable Chronix to emerge as a leader in the cancer diagnostic test field. In addition to our current test menu, we anticipate that Dr Plowman will provide significant guidance in the advancement of diagnostic cancer tests in our developmental pipeline. Chronix is fortunate to have a professional of Nick Plowman’s calibre on board.”

Loading Chronix Biomedical GmbH collaborators
Loading Chronix Biomedical GmbH collaborators